Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 999

1.

Infliximab use in luminal Crohn's disease.

Richter JA, Bickston SJ.

Gastroenterol Clin North Am. 2006 Dec;35(4):775-93. Review.

PMID:
17129813
2.

Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.

Keating GM, Perry CM.

BioDrugs. 2002;16(2):111-48. Review.

PMID:
11985485
3.

A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.

Dretzke J, Edlin R, Round J, Connock M, Hulme C, Czeczot J, Fry-Smith A, McCabe C, Meads C.

Health Technol Assess. 2011 Feb;15(6):1-244. doi: 10.3310/hta15060. Review.

4.

A review of infliximab use in ulcerative colitis.

Wilhelm SM, McKenney KA, Rivait KN, Kale-Pradhan PB.

Clin Ther. 2008 Feb;30(2):223-30. doi: 10.1016/j.clinthera.2008.02.014. Review.

PMID:
18343261
5.
6.

Infliximab in treatment of Crohn's disease: the Milan experience.

Ardizzone S, Colombo E, Maconi G, Bollani S, Manzionna G, Petrone MC, Bianchi Porro G.

Dig Liver Dis. 2002 Jun;34(6):411-8.

PMID:
12132788
7.

Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease--modelling outcomes in active luminal and fistulizing disease in adults.

Lindsay J, Punekar YS, Morris J, Chung-Faye G.

Aliment Pharmacol Ther. 2008 Jul;28(1):76-87. doi: 10.1111/j.1365-2036.2008.03709.x. Epub 2008 Apr 11.

8.

Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.

Vermeire S, Louis E, Carbonez A, Van Assche G, Noman M, Belaiche J, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D'Haens G, Rutgeerts P; Belgian Group of Infliximab Expanded Access Program in Crohn's Disease.

Am J Gastroenterol. 2002 Sep;97(9):2357-63.

PMID:
12358256
9.

Infliximab maintenance therapy for fistulizing Crohn's disease.

Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ.

N Engl J Med. 2004 Feb 26;350(9):876-85.

10.

Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.

Behm BW, Bickston SJ.

Cochrane Database Syst Rev. 2008 Jan 23;(1):CD006893. doi: 10.1002/14651858.CD006893. Review.

PMID:
18254120
11.

Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.

Hlavaty T, Pierik M, Henckaerts L, Ferrante M, Joossens S, van Schuerbeek N, Noman M, Rutgeerts P, Vermeire S.

Aliment Pharmacol Ther. 2005 Oct 1;22(7):613-26.

12.

Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.

Magro F, Portela F.

BioDrugs. 2010 Dec 14;24 Suppl 1:3-14. doi: 10.2165/11586290-000000000-00000. Review.

PMID:
21175228
13.

Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions.

Kinney T, Rawlins M, Kozarek R, France R, Patterson D.

Am J Gastroenterol. 2003 Mar;98(3):608-12.

PMID:
12650795
14.

Infliximab in fistulizing Crohn's disease.

Osterman MT, Lichtenstein GR.

Gastroenterol Clin North Am. 2006 Dec;35(4):795-820. Review.

PMID:
17129814
15.

Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics.

Feagan BG, Enns R, Fedorak RN, Panaccione R, Paré P, Steinhart AH, Wild G.

Can J Clin Pharmacol. 2001 Winter;8(4):188-98. Review.

PMID:
11743591
16.
17.

Similar response to adalimumab in patients with active Crohn's disease either naive to biologic agents or with prior loss of response or intolerance to infliximab.

Triantafillidis JK, Mantzaris G, Karagiannis J, Papavasilliou E, Papatheodoridis G, Fouskas J, Malgarinos G, Gikas A, Papamichael K, Mathou N, Symboulakis E, Karamanolis D.

Rev Med Chir Soc Med Nat Iasi. 2010 Jan-Mar;114(1):85-90.

PMID:
20509281
18.

Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.

Sandborn WJ, Hanauer SB.

Am J Gastroenterol. 2002 Dec;97(12):2962-72. Review.

PMID:
12492177
19.

Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease.

Esters N, Vermeire S, Joossens S, Noman M, Louis E, Belaiche J, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, Poulain D, Bossuyt X, Rutgeerts P; Belgian Group of Infliximab Expanded Access Program in Crohn's Disease.

Am J Gastroenterol. 2002 Jun;97(6):1458-62.

PMID:
12094865
20.

NOD2/CARD15 does not influence response to infliximab in Crohn's disease.

Vermeire S, Louis E, Rutgeerts P, De Vos M, Van Gossum A, Belaiche J, Pescatore P, Fiasse R, Pelckmans P, Vlietinck R, Merlin F, Zouali H, Thomas G, Colombel JF, Hugot JP; Belgian Group of Infliximab Expanded Access Program and Fondation Jean Dausset CEPH, Paris, France.

Gastroenterology. 2002 Jul;123(1):106-11.

PMID:
12105838
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk